Connected profiles4
Exact peptide identities attached to retained registry observations carrying this condition label.
Coverage-gated living condition brief
Diabetes Mellitus, Type 2 peptide evidence brief
A cited Diabetes Mellitus, Type 2 peptide evidence brief across 7 exact-label ClinicalTrials.gov records, 4 connected profiles, and 6 registry-update years. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
Registry records
7 selected records.
Connected peptides
4 profiles.
Registry update years
2014–2026 in selected records.
Direct collection answer · published August 17, 2026
What peptide evidence does PeptideScanner carry for Diabetes Mellitus, Type 2?
PeptideScanner’s selected collection contains 7 retained ClinicalTrials.gov records carrying the exact condition label “Diabetes Mellitus, Type 2,” connected to 4 peptide profiles across 6 registry-update years.
That answer describes this collection and the exact cited registry observations below. It is not a conclusion about whether any peptide treats Diabetes Mellitus, Type 2, and it is not a safety or efficacy assessment.
Indication intelligence
Selected evidence landscape
Trial phases3
Phase labels copied from the retained ClinicalTrials.gov versions.
Phase 1 (4)Phase 3 (2)Phase 4 (1)
Registry statuses3
Overall statuses at each retained observation, not necessarily current today.
Completed (5)Active, not recruiting (1)Recruiting (1)
Across the connected peptide profiles, PeptideScanner also carries 205 selected PubMed records and 23 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Diabetes Mellitus, Type 2 unless their own cited source says so.
Related profile context
Literature connected through these peptide profiles
This is a bounded sample of up to six PubMed bibliography records connected through peptide profiles on this hub, not the total profile literature count above. They are not condition-matched records, and their presence does not establish that they concern Diabetes Mellitus, Type 2.
Semaglutide · source record 2026-09-09
"I Believe in Santa Claus" and Ozempic: A Foucauldian Discourse Analysis of Holiday Health Advertising.
PubMed lists PMID 40536021 in Qualitative health research as Journal Article, with publication-date metadata of 2025-06-19 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Exenatide · source record 2026-09-08
Development of Chondroitin Sulfate ‑ Stabilized PLGA Microspheres of Exenatide via Polarity Gradient Extraction.
PubMed lists PMID 42709517 in Pharmaceutical development and technology as Journal Article, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Liraglutide · source record 2026-09-08
Monitoring Liraglutide Oligomeric Interconversion and Fibril Dissociation through High-Pressure NMR Spectroscopy.
PubMed lists PMID 42708757 in Analytical chemistry as Journal Article, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Maridebart cafraglutide · source record 2026-08-13
Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications.
PubMed lists PMID 42592044 in Antibody therapeutics as Journal Article, Review, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug maridebart-cafraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Semaglutide · source record 2026-09-07
Ozempic and thin line between therapy and dependence.
PubMed lists PMID 42703141 in JPMA. The Journal of the Pakistan Medical Association as Journal Article, with publication-date metadata of 2026-08 (month precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Exenatide · source record 2026-01-30
The use of exenatide in severely burned pediatric patients.
PubMed lists PMID 20701787 in Critical care (London, England) as Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S., with publication-date metadata of 2010-08-11 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
Record added
ClinicalTrials.gov record NCT02981069
PeptideScanner retained ClinicalTrials.gov record NCT02981069 at 2026-07-30T19:10:42.759Z. Its registry update date was 2023-07-20, and PeptideScanner's reviewed identity mapping was exenatide.
- PeptideScanner change date
- September 9, 2026
- Cited source date
- July 20, 2023
- Evidence lane
- Clinical trials
Record added
ClinicalTrials.gov record NCT03811561
PeptideScanner retained ClinicalTrials.gov record NCT03811561 at 2026-09-09T19:17:17.089Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide.
- PeptideScanner change date
- September 9, 2026
- Cited source date
- September 9, 2026
- Evidence lane
- Clinical trials
Record added
ClinicalTrials.gov record NCT07684144
PeptideScanner retained ClinicalTrials.gov record NCT07684144 at 2026-09-09T19:17:17.403Z. Its registry update date was 2026-09-03, and PeptideScanner's reviewed identity mapping was maridebart-cafraglutide.
- PeptideScanner change date
- September 9, 2026
- Cited source date
- September 3, 2026
- Evidence lane
- Clinical trials
Exact-record source chronology
Diabetes Mellitus, Type 2 registry timeline
Years come from the last-update date on each retained ClinicalTrials.gov observation. They show source chronology, not when PeptideScanner added the record and not a continuous monitoring guarantee.
2026
2 recordsSemaglutide · 2026-09-09
ClinicalTrials.gov record NCT03811561
Active, not recruiting at the retained observation.
Open cited registry record →Maridebart cafraglutide · 2026-09-03
ClinicalTrials.gov record NCT07684144
Recruiting at the retained observation.
Open cited registry record →2023
1 recordExenatide · 2023-07-20
ClinicalTrials.gov record NCT02981069
Completed at the retained observation.
Open cited registry record →2019
1 recordSemaglutide · 2019-06-19
ClinicalTrials.gov record NCT03466567
Completed at the retained observation.
Open cited registry record →2018
1 recordSemaglutide · 2018-04-18
ClinicalTrials.gov record NCT02146079
Completed at the retained observation.
Open cited registry record →2017
1 recordSemaglutide · 2017-04-04
ClinicalTrials.gov record NCT02022254
Completed at the retained observation.
Open cited registry record →2014
1 recordLiraglutide · 2014-12-09
ClinicalTrials.gov record NCT01507389
Completed at the retained observation.
Open cited registry record →- Condition matching is limited to exact labels on retained ClinicalTrials.gov v3 observations; PeptideScanner does not merge related diagnoses or synonyms.
- Coverage is selective and historical, not a complete or continuously current account of the registry or PubMed.
- The brief does not synthesize study outcomes, compare interventions, or make safety, efficacy, diagnosis, or treatment claims.